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The nuclear receptor peroxisome proliferator-activated receptor α (PPARα) is activated by a large number of xenobiotic and
hypolipidemic compounds called peroxisome proliferator chemicals (PPCs). One agonist of PPARα (WY-14,643) regulates
responses in the mouse liver to chemical stress in part by altering expression of genes involved in proteome maintenance (PM)
including protein chaperones in the heat shock protein (Hsp) family and proteasomal genes (Psm) involved in proteolysis.
We hypothesized that other PPARα activators including diverse hypolipidemic and xenobiotic compounds also regulate PM
genes in the rat and mouse liver. We examined the expression of PM genes in rat and mouse liver after exposure to 7 diﬀerent
PPCs (WY-14,643, clofibrate, fenofibrate, valproic acid, di-(2-ethylhexyl) phthalate, perfluorooctanoic acid, and perfluorooctane
sulfonate) using Aﬀymetrix microarrays. In rats and mice, 174 or 380 PM genes, respectively, were regulated by at least one PPC.
The transcriptional changes were, for the most part, dependent on PPARα, as most changes were not observed in similarly treated
PPARα-null mice and the changes were not consistently observed in rats treated with activators of the nuclear receptors CAR or
PXR. In rats and mice, PM gene expression exhibited diﬀerences compared to typical direct targets of PPARα (e.g., Cyp4a family
members). PM gene expression was usually delayed and in some cases, it was transient. Dose-response characterization of protein
expression showed that Hsp86 and Hsp110 proteins were induced only at higher doses. These studies demonstrate that PPARα,
activated by diverse PPC, regulates the expression of a large number of genes involved in protein folding and degradation and
support an expanded role for PPARα in the regulation of genes that protect the proteome.

1. Introduction
Peroxisome proliferator chemicals (PPCs) are a large class
of structurally heterogeneous pharmaceutical and industrial
chemicals originally identified as inducers of the size and
number of peroxisomes in rodent livers. The peroxisome
proliferator-activated receptor family is a subset of the
nuclear receptor superfamily and includes three family
members (PPARα, β, and γ). The PPARα subtype plays a
dominant role in mediating the eﬀects of hypolipidemic
and xenobiotic PPC in the liver [1]. Activation of PPARα
results in a predictable set of responses in the livers of

rats and mice, including hepatocyte peroxisome proliferation, hepatomegaly, hepatocyte hyperplasia, and increased
incidence of liver tumors [2]. These responses require a
functional PPARα, since PPARα-null mice exposed to the
PPARα agonists WY or bezafibrate lack all of these responses
[3–5]. PPARα controls these phenotypic responses by regulating a large number of genes in the liver including those
involved in lipid homeostasis such as fatty acid oxidation and
peroxisome assembly.
Various physical or chemical stressors can produce
disease states in which proteins are damaged or misfolded in
part through increases in oxidative stress. Many endogenous
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pathways are activated to restore cellular homeostasis,
including stabilization of unfolded proteins to prevent
aggregation as well as removal of damaged or excess
proteins through proteolysis. Stabilization of unfolded proteins is performed by molecular chaperones that assist
in the folding of nascent polypeptides. Many chaperone
genes exhibit increased expression after exposure to a
wide variety of stimuli including chemical exposure or
increased temperatures and are thus called heat shock
(HS) protein (Hsp) genes [6–8]. These proteins play key
roles in a number of human diseases [9] and are essential
for cellular survival under physical or chemical exposure
conditions that increase oxidative stress [10, 11]. Additional
guardians of the proteome include the genes encoding
components of the proteasome. The proteasome carries
out ubiquitin-dependent and -independent proteolysis of
damaged proteins [12]. The 26S proteasome consists of
a 20S core and two 19S regulatory particles containing a
total of 28 subunits. Proteasomal (Psm) gene expression
can be induced by treating cells with proteasomal inhibitors
[13].
There is compelling evidence that PPARα protects multiple tissues from oxidative stress induced by chemical insults
[14]. The hypolipidemic drug and PPC, clofibrate, protects
the liver from damage from the cytotoxicant acetaminophen
in wild-type but not PPARα-null mice [15]. Compared
to wild-type mice, untreated PPARα-null mice or primary
hepatocytes isolated from PPARα-null mice were more
sensitive to carbon tetrachloride-, paraquat- or cadmiuminduced toxicity [16]. The beneficial eﬀects of caloric
restriction in protecting the liver from cytotoxicant-induced
liver injury were shown to depend on PPARα [17]. In the
kidney, PPARα-null mice were more sensitive to damage
after ischemia-reperfusion injury [18], and prior exposure of
wild-type mice to PPC reduces the injury [19]. Our previous
microarray studies identified PM genes regulated by the
PPARα agonist WY-14,643 (WY) including those involved
in protein folding (e.g., Hsp genes) as well as ubiquitindependent and -independent proteolytic processing through
the proteasome (e.g., Psm genes) [16]. Altered regulation of
these genes by PPC could help to explain why PPC exposure
through PPARα helps to protect tissues from environmental
stressors.
In the present study, we hypothesized that PPARα
activators other than WY also regulate PM genes in the rat
and mouse liver. We examined the expression of PM genes
in rat and mouse liver after exposure to 7 diﬀerent PPC
(WY, clofibrate (CLO), fenofibrate (FENO), valproic acid
(VPA), di-(2-ethylhexyl)phthalate (DEHP), perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS))
using Aﬀymetrix microarrays from published studies. We
show that both therapeutic and environmentally relevant
PPC exposure has a dramatic impact on PM gene expression
in the rat and mouse liver. Although most of the changes were
PPARα-dependent, there were diﬀerences in their temporal
and dose-dependent regulation compared to typical PPARα
target genes involved in fatty acid oxidation. Our findings
suggest PPARα is a major regulator of PM genes that have
an impact on stress responses in the liver.
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2. Materials and Methods
2.1. Animal Studies for Chaperone Protein Expression. The
first study was carried out at CIIT, Centers for Health
Research, Research Triangle Park, NC utilized wild-type
and PPARα-null male mice 9–12 weeks of age on a mixed
SV129/C57BL/6J background and have been described previously [20]. Control and treated mice were provided with
NIH-07 rodent chow (Zeigler Brothers, Gardeners, PA) and
deionized, filtered water ad libitum. Lighting was on a 12hr light/dark cycle. Wild-type and PPARα-null mice were
given seven daily gavage doses of 0.1% methyl cellulose
control (Sigma Chemical Co., St. Louis, MO), or di(2-ethylhexyl)phthalate (DEHP) (1000 mg/kg/bw/day) and
sacrificed 24 hrs after the last dose.
The second study (NTP study number TOX-60) was
carried out at Battelle (Columbus, OH) under a contract
from the National Toxicology Program. Male B6C3F1 mice
at 4–6 weeks of age were obtained from Taconic Farms,
Inc. (Germantown, NY). The feed was NTP-2000 in meal
form (Zeigler Brothers, Inc., Gardners, PA) and the drinking
water was from the City of Columbus municipal supply.
Both feed and water were supplied ad libitum. At 7-8
weeks of age, the mice received in their feed WY at 0, 5,
10, 50, 100, or 500 ppm. The mice were euthanized after
6 days of exposure to WY. Portions of the livers were
rapidly snap-frozen in liquid nitrogen and stored at −70◦ C
until analysis. All animal studies were conducted under
federal guidelines for the use and care of laboratory animals
and were approved by Institutional Animal Care and Use
Committees.
2.2. Animal Studies Used for Microarray Analysis. The experiments related to clofibrate- (CLO-) and valproic acid- (VPA) treated rats were described in Jolly et al. [21]. Briefly, male
Sprague-Dawley rats (n = 5) were given a single dose of
CLO or VPA at the level of 1,000 mg/kg and 2,000 mg/kg,
respectively. Animals were killed at 4, 24, and 48 hrs after
exposure. Eleven-to-12-week-old male Sprague-Dawley rats
were dosed with 20 or 10 mg/kg/day PFOA or PFOS, respectively, in an aqueous solution of 15% Alkamuls EL-620 for 2
days and sacrificed 24 hours later as described in Martin et al.
[22]. The animal study of fenofibrate (FENO) was described
in Sanderson et al. [23]. Male pure-bred SV129 and PPARαnull mice (2–6 months of age) on a SV129 background were
used in the experiments. Fenofibrate was given by gavage
(10 mg/ml suspension in 0.5% carboxymethyl cellulose).
Animals were sacrificed 6 hours after treatment. Four wildtype and PPARα-null male mice (129S1/SvlmJ wild-type
and PPARα-null) per group (6 months of age) were dosed
by gavage for 7 consecutive days with PFOA (3 mg/kg/day)
in distilled water as described in Rosen et al. [24]. At the
end of the dosing period, animals were euthanized by CO2
asphyxiation and liver tissue was collected for preparation of
total RNA.
2.3. Western Blot Analysis. Liver lysates were prepared in
250 mM sucrose, 10 mM Tris-HCl, pH 7.4, and 1 mM EDTA
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with protease inhibitors (0.2 mM phenylmethylsulfonyl fluoride, 0.1% aprotinin, 1 μg/ml pepstatin, 1 μg/ml leupeptin)
as previously described [25]. Fifty μg hepatocyte whole
cell lysate was subjected to 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis followed by transfer to
nitrocellulose membranes. Immunoblots were developed
using primary antibodies against acyl-CoA oxidase (ACO)
(a kind gift from Stefan Alexson, Huddinge University
Hospital, Huddinge, Sweden), HS proteins (Santa Cruz
Biotechnology, Santa Cruz, CA; StressGen, Victoria, B.C.,
Canada) or CYP4A (GenTest, Waltham, MA) and appropriate secondary antibodies conjugated with horseradish
peroxidase (Santa Cruz Biotechnology) in the presence of
chemiluminescent substrate ECL (Amersham, Piscataway,
NJ). Blots were quantitated using Gel-Pro (MediaCybernetics, Silver Spring, MD). Most antibodies recognized only one
major band with the expected size. Antibodies to TCP1η
routinely gave 2 bands: a ∼60 kDa representing the fulllength protein and a possible fragment of ∼40 kDa. In this
study we report the levels of the full-length TCPη and ACO
protein (ACO-A). The expression of ACO-B protein, the
52 kDa processed form of ACO-A [26] was also measured.
There were 3 animals per treatment group. Variability is
expressed as standard error of the mean. Means and S.E.
(n = 3) for western data were calculated by Student’s t-test.
The level of significance was set at P ≤ .05.
2.4. Analysis of Microarray Data. A summary of the microarray studies is shown in Table 1. The doses selected in these
studies would be expected to elicit close to a maximal
transcriptional response. The raw data files analyzed in
this project (.cel files from Aﬀymetrix DNA chips) were
either downloaded from Gene Expression Omnibus (GEO)
or communicated through the original authors. All of the
Aﬀymetrix (Santa Clara, CA) .cel files were first analyzed by
Bioconductor SimpleAﬀy to assess data quality [27]. All .cel
files passed this QC step. Data (.cel files) were analyzed and
statistically filtered using Rosetta Resolver version 7.1 software (Rosetta Inpharmatics, Kirkland, WA). The background
correction was done by Resolver’s specific data processing
pipeline called Aﬀymetrix Rosetta-Intensity Profile Builder.
Statistically significant genes were identified using one-way
ANOVA with a false discovery rate (Benjamini-Hochberg
test) of ≤0.05 followed by a post hoc test (Scheﬀe) for
significance. Fold-change values <1.5 were removed. As most
of the experiments in rats used the RG-U34A array, we
compared profiles in the RG-U34A annotation file from
Aﬀymetrix (http://www.aﬀymetrix.com/analysis/index.aﬀx).
We identified probeset IDs (a total of 8799) on the U34A
chip that exhibited sequence similarity with those on
the RAE230 2 chip using the “good match” comparison
and then built fold-change values for those genes from
the RAE230 2 chip which were altered significantly. Heat
maps were generated using Eisen Lab Cluster and Treeview
software (http://rana.lbl.gov/EisenSoftware.htm). A detailed
description of each experiment is available through Gene
Expression Omnibus at the National Center for Biotechnology Information at http://www.ncbi.nlm.nih.gov/geo/, as
accession numbers indicated in Table 1.
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PM genes were identified using the following gene
ontology identifiers: 0031072:heat shock protein binding,
0006457:protein folding, 009408:response to heat, 0051085
:chaperone cofactor-dependent protein folding, 0006950:response to stress, 0006983:endoplasmic reticulum overload,
0006512:ubiquitin cycle, and 0006511:ubiquitin-dependent
protein catabolic process. A number of proteasome genes
(Psm family) not linked to GO identifiers were also included.

3. Results
Our previous experiments indicated that a PPARα agonist
(WY) alters the expression of PM genes in the mouse liver
including those involved in protein folding and protein
degradation [16]. To determine if other PPARα agonists have
similar activities, we examined transcript profiles in rat and
mouse liver after treatment with compounds that possess
PPARα agonist-like activities including three hypolipidemic
compounds (WY, clofibrate (CLO), fenofibrate (FENO)),
an antiepilepsy drug (valproic acid, VPA), and three environmentally relevant chemicals (the plasticizer, di-(2-ethylhexyl)phthalate (DEHP) and the surfactant processing aids,
perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) (Table 1). PM genes were identified using gene
ontology (GO) identifiers (e.g., protein folding; response to
stress including endoplasmic reticulum overload; ubiquitindependent protein catabolic process).
3.1. Altered Expression of Proteome Maintenance Genes in
the Rat and Mouse Liver after Exposure to Diverse PPC.
We examined gene expression in the livers of rats and
mice treated with PPC. In both species, PPC increased
expression of genes known to be regulated by PPARα
including those involved in fatty acid oxidation such as Cyp4a
family members, acyl-CoA oxidase 1 (Acox1) and peroxisome
assembly genes, for example, Pex11a (Figures 1(a) and 2(a)).
The global expression of all PM genes in the rat and mouse
liver is shown in Figures 1(b) and 2(b), respectively. Out
of a total of 288 PM probe sets identified in the rat, 174
were altered by one or more of the 14 treatment conditions
(Supplemental File 1). Likewise, out of the total of 1597 PM
probe sets examined in the mouse, 382 were altered by one
or more of the 12 treatment conditions (see Supplementary
Material available online at doi:10.1155/2010/727194).
There were a number of similarities exhibited by the
PM genes in both species. First, the altered genes were
dominated by those that were upregulated after exposure.
The upregulated genes outnumbered the downregulated
genes ∼2 to 1. Second, the PM genes exhibited a delay in
altered expression compared to the known direct targets
of PPARα. The direct targets of PPARα were increased as
soon as 4 hrs (rat) or 6 hr (mouse) after initial exposure. In
contrast, almost none of the PM genes in rats were altered
at 4 hrs and some required up to 2 days of exposure before
expression changes were observed. Most of the expression
changes that occurred after WY exposure in the mouse liver
were observed at 5 days but not 6 hrs. Third, a number
of PM genes exhibited transient changes compared to

Jolly et al., 2005 [21]
Nelson et al., 2006
[29]
Sanderson et al., 2008
[23]
Currie et al., 2005
[30]
Rosen et al., 2008
[24]
Sanderson et al., 2008
[23]

Rat

SV129 and
PPARα-null
C57BL/6J

GSE8292,
GSE8295

Not submitted

GSE8295
GSE8396

SV129 and
PPARα-null
SV129 and
PPARα-null

SD

GSE14712

GSE9786

SD

SD

SD (Wistar)

SD (Wistar)

Strain

GSE2303

GSE2303

GSE14712

GSE14712

GEO Accession
number

Once

Once daily

Once daily

Once daily

Once daily

Once

Once

Once daily

Once daily

Dose
frequency

Fenofibrate2

PFOA (3)

DEHP (1150)

WY2

Clofibrate (1000)
PB (100) and PCN
(100)

DEHP (20,000)
Valproic acid (2000)

WY (60)

PFOA (20) and PFOS
(10)

Chemical and (Dose)1
15% Alkamuls

Vehicle

Distilled water

6 hrs

7 days

Distilled water

430 2

Mouse 430 2

Mouse 430 2

2, 8, 24 hrs, 3
days

4

4

3

3–5 (6 hrs)
4 (5 days)

4

RAE230 2.0
Mouse 430 2

3–5

3–5

3

3

16

16

24

17 (6 hrs)
16 (5 days)

36

16

16 (DEHP)
15 (VPA)

12

9

Number of
Total number
biological
of .cel files
replicates

Rat U34A

Rat U34A

RAE230A

RAE230 2.0

Array type

6 hrs, 5 days
Corn oil

4, 24, 48 hrs
0.9% saline
6 hrs, 1 day, 5 1% Tween-80 in 0.5%
days
aqueous methylcellulose

4, 24, 48 hrs

1 day, 3 days,
Carboxymethylcellulose
7 days

3 days

Time of
treatment

All exposure experiments were conducted on male rats or mice by gavage.
1 All doses are in mg/kg/day.
Abbreviations: DEHP: di-2-ethylhexyl phthalate; WY: WY-14,643; PFOA: perfluorooctanoic acid; PFOS: perfluorooctane sulfonate; SD: Sprague-Dawley; PB: phenobarbital; PCN: pregnenolone-16alphacarbonitrile.
2 400 μL of a 10 mg/mL solution/day.

Mouse

Mouse

Mouse

Mouse

Rat

Jolly et al., 2005 [21]

Martin et al., 2007
[22]
Ellinger-Ziegelbauer
et al., 2005 [28]

Reference

Rat

Rat

Rat

Species

Table 1: Characteristics of the studies used in the rat and mouse liver microarray analysis.
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Figure 1: Altered expression of proteome maintenance genes by diverse PPC in rat liver. Male rats were treated with DEHP, VPA, CLO, WY,
PFOA, or PFOS for the indicated times. Hepatic mRNA transcripts were assessed using Aﬀymetrix arrays. Genes involved in PM including
protein chaperones were identified as described in Section 2. (a) Positive control genes. (b) Expression of all PM genes altered by at least one of
the treatments. Genes were clustered using one-dimensional hierarchical clustering. All genes are found in the Supplementary Material. Red:
up-regulation; green: down-regulation; black: no change; grey: no data. The intensity scales indicates fold-change due to chemical exposure
relative to controls. Abbreviations: WY: WY-14,643; DEHP: di-(2-ethylhexyl)phthalate; PFOA: perfluorooctanoic acid; VPA: valproic acid;
CLO: clofibrate; PFOS: perfluorooctane sulfonate.

the constant expression of the direct targets of PPARα. Genes
were induced by DEHP, VPA or CLO at 1 but not 2 days;
in the mouse liver, a subset of genes were induced by DEHP
at 8 hrs but not at any other time. Fourth, there were PPCspecific eﬀects. In the rat VPA, WY and PFOA all increased
unique sets of genes. Another set of genes was increased
by DEHP at day 1 but decreased by VPA and CLO. In the
mouse liver WY, DEHP and FENO altered unique subsets of
genes.
The transcriptional changes were, for the most part
dependent on PPARα, as most changes were not observed in

similarly treated PPARα-null mice. The exceptions included
the altered regulation of 6 genes by WY for 5 days, 1
gene by PFOA for 7 days and 41 genes by fenofibrate for
6 hrs. Although fenofibrate is considered a PPARα agonist,
there is evidence that other fibrates can activate PPARγ in
transactivation assays [1], and pan-PPAR activation may
contribute to PPARα-independent regulation of a subset of
the PM genes. Overall, these results indicate that both fatty
acid metabolizing and PM genes were dependent on PPARα
for altered regulation by PPC. The PM genes exhibited
unique characteristics in their pattern of expression.

6

PPAR Research
Wild-type

F ENO

WY

PFOA

DEHP

F ENO

PFOA

WY

PPARα-null

6 h 5 d 2 h 8 h 24 h 3 d 7 d 6 h 6 h 5 d 7 d 6 h

Wild-type

F ENO

WY

PFOA

DEHP

F ENO

PFOA

WY

PPARα-null

6 h 5 d 2 h 8 h 24 h 3 d 7 d 6 h 6 h 5 d 7 d 6 h
Acox1
Alpl
Cyp4a10
Cyp4a14
Pex11a
Vnn1
−10

0

10

(a)

−2

0

2

(b)

Figure 2: Altered expression of proteome maintenance genes by diverse PPC is predominantly PPARα dependent. Wild-type or PPARαnull mice were treated with WY, DEHP, PFOA, or FENO for the indicated times. Hepatic mRNA transcripts were assessed using fullgenome Aﬀymetrix arrays. Genes involved in PM including protein chaperones were identified as described in Section 2. (a) Positive control
genes. (b) Expression of all PM genes altered by at least one of the treatments. Genes were clustered using one-dimensional hierarchical
clustering. All genes are found in Supplemental Material. Red: up-regulation; green: down-regulation; black: no change. The intensity
scales indicate fold-change due to chemical exposure relative to controls. Abbreviations: WY: WY-14,643; DEHP: di-(2-ethylhexyl)phthalate;
PFOA: perfluorooctanoic acid; FENO: fenofibrate.

3.2. Regulation of Proteasomal Genes by PPC. A large number
of genes encoding components of the proteasome were
altered by WY [16]. We examined the expression of the proteasomal genes (Psm) as well as those known to be involved in
ubiquitin-dependent proteolysis after PPC exposure (Figures
3(a) and 3(b)). In both species all of the Psm genes which
exhibited altered regulation were upregulated except those
that are components of the immunoproteasome (i.e., Psmb8
in rats and Psmb8, Psmb9 and Psmb10 in mice). DEHP and
VPA in rats and WY and PFOA in mice altered the largest
number of Psm genes. In contrast, DEHP in mice transiently
altered only a small set of Psm genes. The changes were never
observed earlier than 1 day in rats. DEHP, VPA and PFOA
in rats and WY and PFOA in mice altered subunits of both

the catalytic core (20S proteasome) and the ATP-dependent
regulatory core (19S proteasome), whereas CLO and WY
in rats preferentially altered 20S components. There were a
number of genes that were altered in both species including
Psma1, Psma5, Psma7, Psmb2, Psmb3, Psmb4, Psmb8, Psmc4,
Psmd1, Psmd4, and Psmd13. All of the Psm genes altered by
PPC in mice were PPARα dependent.
In an examination of the ubiquitination machinery, PPC
altered 8 probesets (6 genes) in rat liver and 48 probesets (35
genes) in mouse liver (data not shown; see Supplemenary
Material). None of the rat genes were altered by more
than two PPC and in the mouse liver, only one gene
(Usp38) was altered by three out of the four PPCs. All
but six of the ubiquitination genes were PPARα dependent.
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Figure 3: Expression of the proteasomal genes in the rat and mouse liver after PPC treatment. Proteasomal gene expression was examined in
the (a) rat liver or (b) mouse liver after PPC exposure using the studies described in Figures 1 and 2. Genes which exhibited altered expression
in at least one of the treatments are shown. Genes are presented in alphabetical order. Many genes were represented by more than one probe
set.

These findings extend the results from our earlier study and
show that diverse PPCs coordinately alter the expression of
the Psm genes in a PPARα-dependent manner.
3.3. Regulation of Protein Chaperone Genes by PPC. We
examined the expression of protein chaperone genes after
PPC exposure (Figures 4(a) and 4(b)). Almost all of the
chaperone genes were upregulated by PPC in rat liver
and by WY in the mouse liver. There were many genes
that were regulated by more than half of the PPC in rat
liver including Hsp90aa1, Hsp90ab1, Hspa8, Hspb1, Hspd1,
Hspe1, Hspa9, and Hsph1. In the mouse liver most of the
PPC regulated a smaller set of genes including Dnaja2,
Grpel2, Hsp90aa1, Hspa4l, Hspa8, Hspb1, and Hsph1. Many
genes were commonly regulated in both species by at least
half of the PPC (Dnaja1, Dnaja2, Hsp90aa1, Hspa1a/b,
Hspa8, Hspb1, Hspd1, Hspe1, Hspa9, and Hsph1). Some

of the changes were transient, exhibiting attenuated or no
regulation after long-term exposure. For WY (Figure 4(b)),
these included Dnaja1, Dnajb1, Dnajb4, Hspa1a, Hspa1b,
Hspa8, Hsph1, and Hsp90aa1 and for DEHP, these included
Dnaja1, Dnaja2, Dnajc12, Grpel2, Hsp90aa1, Hspb1, and
Hspb8. There were a number of chaperone genes that were
uniquely regulated by VPA (Dnaja4, Hspa4), PFOA (Hspa9apredicted) or both (Hspa1b) in rat liver. Exposure to DEHP
in the mouse for 3 days gave a unique pattern of changes in
which Dnaja1, Dnajb1, Dnajb4, Hspa1a, Hspa1b, and Hsph1
were downregulated at 3 days compared to the consistent
up-regulation by the other PPC. Furthermore, three of
these genes (Hspa1a, Hspa1b, Hsph1) were upregulated after
shorter-term exposure. These results indicate that multiple
and possibly competing mechanisms may be regulating these
genes after DEHP exposure, diﬀerent from that of other PPC.
In the mouse liver, most of the genes required PPARα for
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Figure 4: Expression of the protein chaperone genes in the rat and mouse liver after PPC treatment. Protein chaperone gene expression was
examined in the (a) rat liver or (b) mouse liver after PPC exposure using the studies described in Figures 1 and 2. Genes which exhibited
altered expression in at least one of the treatments are shown. Genes are presented in alphabetical order. Many genes were represented by
more than one probe set.

altered expression except for Dnaja3, Grpel2, and Hsp90b1
that appeared to be regulated similarly by FENO in wild-type
and PPARα-null mice.
3.4. Expression of Chaperone Proteins in Mouse Liver after PPC
Exposure. We examined expression of protein chaperones in
protein extracts from livers of mice given five diﬀerent doses
of WY for 6 days or DEHP at one dose level for 7 days.
Given the transcriptional increases in chaperonin-containing
T-complex 1 (Tcp-1) family members Cct3, Cct4, Cct7, and

Cct8 after exposure to PPC in wild-type mice (Supplemental
Material), we also examined the expression of Tcp1η protein.
Dose-dependent increases in Tcp1η, Hsp86, Cyp4A, ACO-A
and Hsp110 were observed in WY-treated wild-type B6C3F1
mice (Figure 5(a)). The chaperones exhibited dissimilar
dose-dependent inductions as TCP1η was induced at lower
doses similar to the direct PPARα targets ACO-A and
Cyp4a, whereas Hsp86 and Hsp110 were induced only at
the higher doses. Induction of Hsp25 and Hsp70 was strain
specific; induction by WY was observed in SV129 mice [31]
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Figure 5: Expression of chaperone proteins after PPC treatment. (a) Protein expression in the livers of mice treated with diﬀerent doses of
WY. B6C3F1 mice were treated with the indicated concentrations of WY in the diet for 6 days. Protein expression was assessed by Westerns
using primary antibodies against the indicated proteins. Blots were quantitated as described in Section 2. (b) Protein expression in livers of
wild-type and PPARα-null mice after exposure to DEHP. Proteins were extracted from the livers of wild-type or PPARα-null mice given 7
consecutive doses of DEHP (1000 mg/kg day). There were 3 animals per treatment group. Variability is expressed as standard error of the
mean. Means and S.E. (n = 3) for western data were calculated by Student’s t-test. The level of significance was set at P ≤ .05 and significance
is indicated with ∗.

but not in B6C3F1 mice (data not shown). Like ACO-A and
ACO-B proteins, induction of Tcp1η, Hsp70, Hsp86, and
Hsp110 protein expression was observed after exposure to
DEHP in wild-type but not PPARα-null mice (Figure 5(b)).
These results demonstrate that diverse PPC induce protein
chaperone expression dependent on PPARα.
3.5. Comparison of the Proteome Maintenance Genes Altered
by Chemicals That Activate Other Nuclear Receptors. Many
of the PM genes have been shown to be induced under
conditions of stress leading to the hypothesis that the
response to PPC may be due to activation of a generalized
stress response. If that was the case, we would predict that the
genes would be altered by other chemicals given at relatively
high doses. To determine the specificity of the PPC response,
the expression changes of the PM genes were compared
between PPC and chemicals which activate other nuclear
receptors: phenobarbital (PB) which activates CAR and
pregnenolone-16alpha-carbonitrile (PCN) which activates
the pregnane X receptor (PXR). In a published study [29],

PB, or PCN were given to rats at 100 mg/kg/day for 6 hrs,
1 day or 5 days. Microarray analysis was performed using
the same microarray platform and analysis procedures as
described above. We compared the PM genes and found that
out of the genes that were altered by PPC, PB or PCN, most
of the genes were uniquely altered by the PPC (Figure 6(a)).
In contrast, only 3 genes were altered by PB and/or PCN
but not any of the PPC. There were 47 overlapping genes
which exhibited for the most part similar expression by the
PPC and PB or PCN (Figure 6(b)). In particular, there was
a group of genes that were consistently upregulated by PB,
PCN and two or more PPC including Ppil3, Psma2, Psma7,
Psmb2, Psmb3, Psmb4, Psmb5, Psmc4, and Psmc5. Due to
their promiscuous induction by most of the chemicals, we
hypothesize that these genes were altered due to a generalized
stress response and not due to activation of a particular
nuclear receptor. However, most of the PM genes that were
altered by PPC formed a unique group that was only altered
by one or more PPC but not by activators of other nuclear
receptors.
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Figure 6: Comparison of the expression of the PM genes after exposure to PPARα, CAR and PXR activators. Lists of diﬀerentially regulated
genes were generated after exposure to phenobarbital (PB), pregnenolone-16alpha-carbonitrile (PCN) or the PPC. The expression of the
PM genes (probe sets) were compared between the treatments. (a) Overlap in the PM gene probesets that were altered in one or more of the
three time points after PB or PCN exposure or after 3 or 4 of the 4 PPC treatment groups are shown. (b) The 47 overlapping gene probe sets
were clustered as described above.

4. Discussion
The nuclear receptor PPARα is considered a key factor in
lipid homeostasis. There is increasing evidence that PPARα
plays additional functional roles in the liver by regulating
responses to various chemical and physical stressors [14]. An
agonist of PPARα (WY) regulates responses in the mouse
liver to chemical stress in part by altering expression of genes
involved in proteome maintenance (PM) such as the Hsp
genes involved in protein folding and Psm genes involved
in proteolysis. In this study, we show that other PPARα
activators including diverse hypolipidemic and xenobiotic
compounds also regulate a common set of PM genes in

the rat and mouse liver. These transcriptional changes were,
for the most part dependent on PPARα because most of
the altered genes were altered by PPC but not by chemicals
that activate other nuclear receptors, CAR and PXR. In mice
the changes in the PM genes were observed in wild-type
but not PPARα-null mice. The responsive PM genes did not
exhibit the same transcriptional behavior as genes known
to be direct targets of PPARα (e.g., Acox1 or Cyp4a family
members) in which PPARα binds directly to peroxisome
proliferator response elements (PPRE) in their promoters.
While the direct targets were upregulated early after exposure
and remained elevated throughout the duration of the
experiment, the PM genes exhibited a lag before expression
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changed and in many cases, the changes were transient.
A number of PM genes were identified that were not
universally regulated by all of the PPC. Discordance in the
expression pattern between the PPC could be explained
in part due to the selection of dose and time which can
both influence the gene expression results of these studies.
However, our studies indicate that the PM genes are a unique
subset of PPARα target genes that appear to be regulated by a
mechanism diﬀerent than fatty acid oxidation genes.
How are the PM genes regulated by PPC through PPARα?
Given that Hsp gene expression is controlled in part by
heat shock factor 1 (HSF1), one possibility is that the
increases in Hsp gene expression are secondary to increases
in the expression and activity of HSF1. However, we did
not observe changes in HSF1 expression in our transcript
profiling studies and earlier studies showed that HSF1 and
HSF2 expression and binding to HSE were not altered by
WY exposure in the rat liver [32]. To help determine whether
regulation of Hsp gene expression is direct or indirect, we
examined their promoters and found that only a few genes
possess a putative PPRE(s) (data not shown). The fact that
most of the Hsp and Psm genes are not immediately increased
by PPC exposure indicates that additional molecular events
are required before induction can occur.
Many Hsp genes may be regulated indirectly through
generalized stress responses especially those that are induced
after exposure to the relatively high doses of the chemicals
used in the animal studies. One of the stress responses that
may be driving the expression of the genes is increases in
oxidative stress. There is abundant evidence for the increased
expression of chaperone gene expression by oxidative stress
[10, 33]. PPC exposure leads to increases in oxidative stress
and lipid peroxidation mediated through increased activities
of enzymes that generate reactive oxygen species (reviewed
in [2]). Furthermore, as oxidative stress after PPC exposure
is a relatively high dose phenomenon [2], the induction
of Hsp86 and Hsp110 only at high doses is consistent
with an indirect mechanism of induction, possibly through
increases in oxidative stress. Likewise, induction of Psm gene
expression may be an adaptation to decreases in the levels
of functional proteasomes through damage by oxidative
stress. Treatment of cells in vitro with proteasome inhibitors
increased the expression of a broad range of subunits of the
proteasome in diverse species [13, 34] even when less than
50% of the total proteasomal activity was inhibited [13].
Proteasome inhibition resulted in increased expression of
19S and 20S components but decreased expression of Psmb8
[13], a pattern similar to that observed with PPC. Since
direct oxidative modification of the catalytic core subunits
of the proteasome inhibits their activities [35], PPC may
be increasing the level of oxidized proteins that inhibit the
proteasome, triggering compensatory increases in Psm genes.
Lastly, the absolute increases in expression of some Hsp
and Psm genes was higher in WY-treated mice nullizygous
for Nrf2, a transcription factor activated by oxidative stress
that regulates genes that dampen oxidative stress. Thus,
in the absence of Nrf2, increased levels of oxidative stress
may have contributed to the greater increases in the PM
genes by WY [16]. Taken together, these results indicate that
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PPARα may regulate the PM genes secondary to increases in
oxidative stress. An alternative hypothesis is that PM genes
are induced in response to the demand for folded proteins
under conditions of increased protein synthesis during active
reprogramming of gene expression coincident with increases
in peroxisomes and smooth endoplasmic reticulum (SER)
and increases in cell number. This hypothesis is consistent
with the fact that a subset of the PM genes were induced by
CAR, PXR as well as PPARα activators, all of which induce
SER proliferation and hepatocyte proliferation. This would
also help to explain the somewhat transient nature of the
gene expression changes as after acute exposure the liver
reaches a new equilibrium in which hepatocyte proliferation
returns to normal levels. Further experiments are needed to
determine the molecular basis for the induction of the PM
genes.
What might the increased levels of PM proteins be doing
in the liver after WY exposure? Increased levels of PM gene
products might allow tight control of the inducibility of
PPARα. Many nuclear receptors interact with chaperone
proteins including the ones induced by PPC in our studies
[36]. PPARα interacts with Hsp72 [37] and is inhibited
by Hsp90 [38]. PPARα activation is also downregulated by
proteasomal proteolysis [39]. Thus, induction of some PM
genes may dampen the PPARα transcriptional response. Hsp
induction may also help support the increases in protein
synthesis required for liver enlargement including peroxisome proliferation after PPC exposure. Increased expression
of TCP1 subunits may be important for proper protein
insertion into the peroxisomal membrane [40]. Increased
expression of Hsp family members has been mechanistically
linked to protection from apoptosis [41, 42] and PPC, at
least under acute exposure conditions, decrease basal levels
of apoptosis [2].
A fundamental question arises as to why PPARα would
have a dual role of regulating both PM genes involved in
stress responses and lipid metabolism genes. The ability of
PPARα to act as a regulator of responses to diﬀerent types
of stressors may have coevolved and become inexorably
linked with the most important stressor mammals face
in the wild, that is, an inadequate or inconsistent food
supply. Periods of starvation or caloric restriction requires
a reprogramming of gene expression to utilize stored fat and
to allow adaptation to new, potentially toxic food sources.
PPARα is a master regulator of the starvation response. Gene
expression changes by fasting [43, 44] or caloric restriction
[14, 17] partly depend on PPARα including genes that
mobilize, transport and catabolize fats. The ability of PPARα
to also regulate genes (e.g., Hsp family members) involved
in suppression of cytotoxicity induced by unfolded proteins
would make teleological sense and may allow increased
resistance to potentially toxic foods animals are forced to eat
when the customary foods are no longer available.
In summary, we used transcript profiling to show that
PPARα activated by diverse PPC regulates the expression
of two classes of genes that may be responsible for protection from chemical-induced oxidative stress: the chaperone
genes involved in protein folding and genes involved in
proteasomal degradation of damaged proteins. Induction of
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these potentially protective pathways may provide eﬃcient
means for cells to survive conditions of oxidative stress that
contribute to chronic diseases. Induction of these pathways
through pharmacological means provides opportunities for
protection in a number of settings in which there is
induction of oxidative stress, oxidative damage to proteins,
and increased occurrence of disease.
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[10] M. Åkerfelt, D. Trouillet, V. Mezger, and L. Sistonen, “Heat
shock factors at a crossroad between stress and development,”
Annals of the New York Academy of Sciences, vol. 1113, pp. 15–
27, 2007.
[11] R. Arya, M. Mallik, and S. C. Lakhotia, “Heat shock genes—
integrating cell survival and death,” Journal of Biosciences,
vol. 32, no. 3, pp. 595–610, 2007.
[12] A. L. Goldberg, “Protein degradation and protection against
misfolded or damaged proteins,” Nature, vol. 426, no. 6968,
pp. 895–899, 2003.
[13] S. Meiners, D. Heyken, A. Weller et al., “Inhibition of proteasome activity induces concerted expression of proteasome
genes and de novo formation of mammalian proteasomes,”
Journal of Biological Chemistry, vol. 278, no. 24, pp. 21517–
21525, 2003.
[14] J. C. Corton and H. M. Brown-Borg, “Peroxisome proliferatoractivated receptor γ coactivator 1 in caloric restriction and
other models of longevity,” Journals of Gerontology A, vol. 60,
no. 12, pp. 1494–1509, 2005.
[15] C. Chen, G. E. Hennig, H. E. Whiteley, J. C. Corton, and J. E.
Manautou, “Peroxisome proliferator-activated receptor alphanull mice lack resistance to acetaminophen hepatotoxicity
following clofibrate exposure,” Toxicological Sciences, vol. 57,
no. 2, pp. 338–344, 2000.
[16] S. P. Anderson, P. Howroyd, J. Liu et al., “The transcriptional
response to a peroxisome proliferator-activated receptor α
agonist includes increased expression of proteome maintenance genes,” Journal of Biological Chemistry, vol. 279, no. 50,
pp. 52390–52398, 2004.
[17] J. C. Corton, U. Apte, S. P. Anderson et al., “Mimetics of
caloric restriction include agonists of lipid-activated nuclear
receptors,” Journal of Biological Chemistry, vol. 279, no. 44,
pp. 46204–46212, 2004.

14
[18] D. Portilla, G. Dai, J. M. Peters, F. J. Gonzalez, M. D.
Crew, and A. D. Proia, “Etomoxir-induced PPARα-modulated
enzymes protect during acute renal failure,” American Journal
of Physiology, vol. 278, no. 4, pp. F667–F675, 2000.
[19] A. Sivarajah, P. K. Chatterjee, Y. Hattori et al., “Agonists of
peroxisome-proliferator activated receptor-α (clofibrate and
WY14643) reduce renal ischemia/reperfusion injury in the
rat,” Medical Science Monitor, vol. 8, no. 12, pp. BR532–BR539,
2002.
[20] S. S. T. Lee, T. Pineau, J. Drago et al., “Targeted disruption
of the α isoform of the peroxisome proliferator- activated
receptor gene in mice results in abolishment of the pleiotropic
eﬀects of peroxisome proliferators,” Molecular and Cellular
Biology, vol. 15, no. 6, pp. 3012–3022, 1995.
[21] R. A. Jolly, K. M. Goldstein, T. Wei et al., “Pooling samples
within microarray studies: a comparative analysis of rat liver
transcription response to prototypical toxicants,” Physiological
Genomics, vol. 22, pp. 346–355, 2005.
[22] M. T. Martin, R. J. Brennan, W. Hu et al., “Toxicogenomic
study of triazole fungicides and perfluoroalkyl acids in rat
livers predicts toxicity and categorizes chemicals based on
mechanisms of toxicity,” Toxicological Sciences, vol. 97, no. 2,
pp. 595–613, 2007.
[23] L. M. Sanderson, P. J. de Groot, G. J. E. J. Hooiveld et
al., “Eﬀect of synthetic dietary triglycerides: a novel research
paradigm for nutrigenomics,” PLos One, vol. 3, no. 2, Article
ID e1681, 2008.
[24] M. B. Rosen, J. S. Lee, H. Ren et al., “Toxicogenomic dissection
of the perfluorooctanoic acid transcript profile in mouse liver:
evidence for the involvement of nuclear receptors PPARα and
CAR,” Toxicological Sciences, vol. 103, no. 1, pp. 46–56, 2008.
[25] LI. Q. Fan, J. Coley, R. T. Miller, R. C. Cattley, and J.
C. Corton, “Opposing mechanisms of NADPH-cytochrome
P450 oxidoreductase regulation by peroxisome proliferators,”
Biochemical Pharmacology, vol. 65, no. 6, pp. 949–959, 2003.
[26] J. C. Corton, LI. Q. Fan, S. Brown et al., “Down-regulation
of cytochrome P450 2C family members and positive acutephase response gene expression by peroxisome proliferator
chemicals,” Molecular Pharmacology, vol. 54, no. 3, pp. 463–
473, 1998.
[27] C. L. Wilson and C. J. Miller, “Simpleaﬀy: a bioConductor
package for aﬀymetrix quality control and data analysis,”
Bioinformatics, vol. 21, no. 18, pp. 3683–3685, 2005.
[28] H. Ellinger-Ziegelbauer, B. Stuart, B. Wahle, W. Bomann, and
H. J. Ahr, “Comparison of the expression profiles induced
by genotoxic and nongenotoxic carcinogens in rat liver,”
Mutation Research, vol. 575, no. 1-2, pp. 61–84, 2005.
[29] D. M. Nelson, V. Bhaskaran, W. R. Foster, and L. D.
Lehman-McKeeman, “p53-independent induction of rat hepatic Mdm2 following administration of phenobarbital and
pregnenolone 16α-carbonitrile,” Toxicological Sciences, vol. 94,
no. 2, pp. 272–280, 2006.
[30] R. A. Currie, V. Bombail, J. D. Oliver et al., “Gene ontology
mapping as an unbiased method for identifying molecular
pathways and processes aﬀected by toxicant exposure: application to acute eﬀects caused by the rodent non-genotoxic carcinogen diethylhexylphthalate,” Toxicological Sciences, vol. 86,
no. 2, pp. 453–469, 2005.
[31] B. Vallanat, S. P. Anderson, H. M. Brown-Borg et al.,
“Analysis of the heat shock response in mouse liver reveals
transcriptional dependence on the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha),”
BMC Genomics, vol. 11, p. 16, 2010.

PPAR Research
[32] M. L. O’Brien, M. L. Cunningham, B. T. Spear, and H.
P. Glauert, “Peroxisome proliferators do not activate the
transcription factors AP-1, early growth response-1, or heat
shock factors 1 and 2 in rats or hamsters,” Toxicological
Sciences, vol. 69, no. 1, pp. 139–148, 2002.
[33] I. J. Benjamin and D. R. McMillan, “Stress (heat shock)
proteins molecular chaperones in cardiovascular biology and
disease,” Circulation Research, vol. 83, no. 2, pp. 117–132, 1998.
[34] S. Mnaimneh, A. P. Davierwala, J. Haynes et al., “Exploration
of essential gene functions via titratable promoter alleles,” Cell,
vol. 118, no. 1, pp. 31–44, 2004.
[35] M. Demasi, G. M. Silva, and L. E. S. Netto, “20 S proteasome from Saccharomyces cerevisiae is responsive to redox
modifications and is S-glutathionylated,” Journal of Biological
Chemistry, vol. 278, no. 1, pp. 679–685, 2003.
[36] R. I. Morimoto, “Dynamic remodeling of transcription complexes by molecular chaperones,” Cell, vol. 110, no. 3, pp. 281–
284, 2002.
[37] Q. Huang, K. Alvares, R. Chu, C. A. Bradfield, and J. K. Reddy,
“Association of peroxisome proliferator-activated receptor and
Hsp72,” Journal of Biological Chemistry, vol. 269, no. 11,
pp. 8493–8497, 1994.
[38] W. K. Sumanasekera, E. S. Tien, J. W. Davis, R. Turpey,
G. H. Perdew, and J. P. V. Heuvel, “Heat shock protein90 (Hsp90) acts as a repressor of peroxisome proliferatoractivated receptor-α (PPARα) and PPARβ activity,” Biochemistry, vol. 42, no. 36, pp. 10726–10735, 2003.
[39] C. Blanquart, O. Barbier, J. C. Fruchart, B. Staels, C.
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